Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Systemic aztreonam only; not inhaled aztreonam lysine. The original 125 mg dialysis comment is not one-eighth of every possible initial dose; the source paragraph specifies one-eighth of the initial dose. Both are preserved as a source discrepancy.
Check source scope before reading a dose
UCSF - systemic aztreonam
Product / population
Adults; single-agent systemic IV aztreonam. Combination-use comments are specialist-specific.
Renal method
CrCl in mL/min where specified; no equation inferred.
Source revision
Revision date not stated in the reviewed page.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.
UCSF Infectious Diseases Management Program · Adults; single-agent systemic IV aztreonam. Combination-use comments are specialist-specific.
Renal method: CrCl in mL/min where specified; no equation inferred. Source date: Revision date not stated in the reviewed page. Retrieved: 2026-09-05
Locally included source-specific summary. Regimen differences are not automatically resolved.
Dosing / renal protocol and limits
IV regimen by CrCl: above 50, 2 g every 8 hours; 10-50, 2 g every 12 hours; below 10, 1 g every 12 hours. IHD: 2 g initially, then each evening. CVVHD: 2 g every 12 hours.
Selected meningitis or resistant Gram-negative cases may require 2 g every 6 hours under specialist direction. When combined with ceftazidime/avibactam for selected resistant infections, both may be infused over 3 hours; simultaneous dosing is preferred when intervals coincide. This is a systemic aztreonam protocol, not inhaled aztreonam or fixed-combination EMBLAVEO.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.